About Ascendo Biotechnology

Jang-Yang Chang, MD— Distinguished Investigator & Director, Institute of Biotechnology and Pharmaceutical Research, NHRI

Medical oncologist and translational research leader bridging academia, hospitals and national drug development

• Current — Distinguished Investigator & Director, Institute of Biotechnology and Pharmaceutical Research (IBPR), National Health Research Institutes
• Academic — Professor Emeritus and former Executive Vice President, National Cheng Kung University (NCKU)
• Prior — Director, National Institute of Cancer Research, NHRI; Chief of Medical Oncology, Tri-Service General Hospital

Shyh-Yuh Liou, Ph.D. — Exclusive Advisor, Ono Pharmaceutical

Translational medicine and clinical pharmacology leader with deep Japan pharma experience

• Current — Exclusive Advisor, Translational Medicine Center & Discovery Technology Research Laboratories, Ono Pharmaceutical
• Prior — Director, Clinical Pharmacology Group, Takeda Pharmaceuticals; Director, Biomarker & Pharmacogenomics, Translational Unit, Takeda Pharmaceuticals
• Expertise — Translational medicine, clinical pharmacology, biomarker and pharmacogenomic strategy

Frank Lee, Ph.D. — DMPK leader across four global pharmaceutical companies

• Prior — Senior Director of DMPK, Millennium Pharmaceuticals; Director of DMPK, DuPont Pharmaceuticals; Section Head of DMPK, Glaxo Wellcome; Senior Chemist, DMPK, Syntex Pharmaceuticals
• Expertise — Drug metabolism and pharmacokinetics, from discovery support through development

Tony Ho, MD, PhD — CSO / Senior Science Partner, Pivotal BioVentures
Physician-scientist and drug development leader spanning oncology, gene editing and neurology

• Current — CSO / Senior Science Partner, Pivotal BioVentures
• Industry — EVP, Head of R&D, CRISPR Therapeutics; SVP, Oncology Innovation & Integration, AstraZeneca
• Academic — Adjunct Associate Professor of Neurology, University of Pennsylvania; former Assistant Professor of Neurology, Johns Hopkins University

Ping Yang Yeh, PhD— 30+ years in biologics R&D, CMC, manufacturing and commercialization

• Industry — Senior leadership at Amgen, Biogen, GSK; CTO & VP, EirGenix; General Manager, AltruBio Taiwan
• Track record — 18 commercial product launches (Repatha®, Blincyto®, Aimovig®, Kyprolis®, Tysabri®, Plegridy®); 45+ US/EU IND and regulatory filings
• Expertise — Protein therapeutics, monoclonal antibodies, CMC strategy, CDMO operations
• Now — Investing in next-wave biotech and medtech innovation
• Education — Ph.D., Molecular Pharmaceutics, University of Utah (advisor: Prof. Jindřich Kopeček); Executive Education, MIT Sloan

Ph.D. in Pharmaceutics, University of Connecticut. General Manager, Beiley Pharmaceuticals. VP of Global Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals Japan. Senior Director, Bristol-Myers Squibb (BMS).

Chief of Chest Medicine, MacKay Memorial Hospital, Taipei. Lead investigator for immunotherapy drug development in tuberculosis and sepsis. Originator of the TLT-1/CD11b checkpoint hypothesis published in the Journal of Immunology (2023).

A serial entrepreneur with 20+ years in asset management, biomedicine and e-commerce. Founder of CGSICE (Taiwan master agent for AXA IM and Old Mutual Global Investors), Ceres Biomedical and NUWA Biomedical; formerly Regional Director for Asia at Hutchison-Priceline.

MBA, George Washington University. Vice Chairman, Taishin Financial Holdings. Chairman, Shin Kong Financial Holdings and Shin Kong Life Insurance. Former Commissioner, Financial Supervisory Commission (Insurance Bureau), Executive Yuan.

Kevin holds a Ph.D. in Biomedical Engineering from University College London. He has served as Senior Director of Business Development and Clinical Development at Steminent Biotherapeutics, and as Senior Investment Manager at Taiwania Capital, bringing deep expertise in both biotech development and life science venture investment.